The FDA has approved Johnson & Johnson’s Spravato nasal spray as a standalone treatment for adults with treatment-resistant depression. This marks the first time a nasal spray has been approved for this condition, which affects about one-third of the 21 million U.S. adults with major depression. Spravato, which hit the market in 2019, has shown sales of $780 million in the first nine months of 2024. The drug, related to ketamine, offers rapid symptom relief, with improvements seen within 24 hours and lasting at least a month. It’s administered in certified health-care settings due to potential side effects like sedation and dissociation. Despite a slow start due to the challenges of the pandemic, Spravato’s sales are expected to grow significantly, with projections between $1 billion and $5 billion annually.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
